Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798376 | 0.77 | DRD2 (0.53) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL4538637 | 0.77 | LTA4H (0.40) | HTR1ACYP3A4SLC6A4 | |
| SCHEMBL4907152 | 0.76 | HTR1A (0.55) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL4197898 | 0.76 | HTR1A (0.55) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL4341944 | 0.76 | HTR1A (0.33) | HTR1ACA2CYP3A4CYP2C8DRD2 | |
| Hydrochloric Acid SCHEMBL5508210 | 0.75 | HTR1A (0.54) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL4483963 | 0.75 | HTR1A (0.54) | HTR1ACYP3A4CYP2C8DRD2DRD4 | |
| SCHEMBL6796425 | 0.74 | HTR1A (0.42) | HTR1ACYP3A4DRD2DRD4CYP2C19 | |
| SCHEMBL6792066 | 0.74 | LMNA (0.38) | HTR1ACA2CYP3A4CYP2C8DRD2 | |
| SCHEMBL4336064 | 0.73 | CA2 (0.32) | HTR1ACA2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800642-B2 | SUCH AS BENZYL-(-7,8-DIHYDRO-2,6,9-TRIOXA-3-AZA-CYCLOPENTA(A)NAPHTHALEN-8-YLMETHYL) -AMINE; FOR TREATMENT OF DRUG DEPENDENCE/ADDICTION, BIPOLAR DISORDER, PARKINSON'S DISEASE, LEVODOPA INDUCED PSYCHOSES OR DYSKINESIAS | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20020198217-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-2,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2002088141-A2 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-2,6,9-TRIOXA-3-AZA-CYCLOPENTA[a]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198217-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-2,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | SNCA, SYNJ2, PARK7 | HTR1A 45/4885CA2 4612/4885CYP3A4 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.